Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1128688 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1128688 [Dose1] | EXPERIMENTAL | BAY1128688 dose level 1 |
| BAY1128688 [Dose2] | EXPERIMENTAL | BAY1128688 dose level 2 |
| BAY1128688 [Dose3] | EXPERIMENTAL | BAY1128688 dose level 3 |
| BAY1128688 [Dose4] | EXPERIMENTAL | BAY1128688 dose level 4 |
| Placebo | PLACEBO_COMPARATOR | Placebo to match arm 1,2, 3 and 4 |
| Name | Type | Description |
|---|---|---|
| BAY1128688 | DRUG | Part A: Single dose and multiple dose for 14 days (postmenopausal women) |
| Placebo | DRUG | Part A: Single dose and multiple dose for 14 days (postmenopausal women) |
Inclusion Criteria: PART A * Postmenopausal state, revealed by 1. Medical history. One of the following: * Natural menopause at least 12 months prior to first study drug administration, * Surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administ...
BAY1128688 is an investigational small molecule being developed for endometriosis. It is an endocrine therapy candidate that has been studied in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
BAY1128688 is being developed by Bayer AG, a German pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker BAYRY. The drug is an investigational small molecule for the treatment of endometriosis.
BAY1128688 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is not yet approved. It is being studied as a potential treatment for endometriosis, but further clinical development is required.
BAY1128688 has one completed clinical trial, NCT02434640, an ascending dose study to investigate the safety, tolerability, and pharmacokinetics of BAY1128688 after multiple oral administrations in healthy women. The trial enrolled 51 participants in Germany and was placebo-controlled and double-blind.
BAY1128688 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is being studied for endometriosis, but it has not received regulatory approval and remains in clinical development.